MaxCyte Minutes – Q4 2018

Industry News, Maxcyte Science, Updates & Events

While monoclonal antibodies continue to provide powerful therapeutic solutions, it’s become clear that effective treatments for complex diseases such as cancer, neurodegenerative diseases, auto-immune disorders and depression cannot simply target a single molecule in the pathological pathway. For this and other reasons, bispecific antibodies (bsAbs) are finding a seat at the table.


Bispecific Playgrounds? No, Factory Floors

Poster: Production & Functional Characterization of Bispecifics and Other Novel Antibody Derivatives Using Scalable, Regulatory-compliant Cell Engineering

Tips from our Experts: